<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307658</url>
  </required_header>
  <id_info>
    <org_study_id>P991006</org_study_id>
    <nct_id>NCT00307658</nct_id>
  </id_info>
  <brief_title>Intravenous Immunoglobulin After Relapse in Vasculitis</brief_title>
  <official_title>Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener’s Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <brief_summary>
    <textblock>
      The aim of this study is to study the efficacy of intravenous immunoglobulins for inducing
      remission in patients relapsing of systemic vasculitides.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study will assess the effects of intravenous immunoglobulin in ANCA+
      vasculitides (Microscopic Polyangiitis, Wegener’s granulomatosis and Churg-Strauss syndrome)
      who relapse under corticosteroid and immunosuppressant therapies or after one year post
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2001</start_date>
  <completion_date>July 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the remission rate after 9 months of therapy with intravenous immunoglobulins,</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>in relapsing patients with ANCA+ vasculitides (Microscopic Polyangiitis, Wegener’s granulomatosis and Churg-Strauss syndrome)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>during 6 months, after relapse</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, i.e. side-effects classified according to the WHO guidelines</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>ANCA + Vasculitides Relapsing Either Under Corticosteroid</condition>
  <condition>and Immunosuppressant Therapies or After One Year</condition>
  <condition>Post Treatment.</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous immunoglobulins (human immunoglobulins G)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Wegener’s granulomatosis, Microscopic polyangiitis and Churg-Strauss syndrome
             (satisfying ACR or chapel Hill classification) relapsing either under corticosteroid
             and immunosuppressant therapies or after one year post treatment

          -  Age &gt; 18 years old

          -  Written informed consent

        Exclusion Criteria:

          -  Systemic vasculitides not previously treated with corticosteroid and
             immunosuppressant(s)

          -  Systemic vasculitides treated with corticosteroids and immunosuppressant therapies,
             but with treatment cessation more than 12 months ago

          -  Polyarteritis nodosa

          -  Absence of poor prognosis criteria (according to FFS)

          -  Nephritis ± renal impairment

          -  Cancer or malignancy

          -  Psychiatric disease, lack of compliance

          -  Age under 18 years old

          -  Lack of written informed consent

          -  Other vasculitides (post viral infection and skin localisation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loïc GUILLEVIN, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital COCHIN</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2006</study_first_submitted>
  <study_first_submitted_qc>March 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2006</study_first_posted>
  <last_update_submitted>May 18, 2006</last_update_submitted>
  <last_update_submitted_qc>May 18, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2006</last_update_posted>
  <keyword>ANCA associated Vasculitides</keyword>
  <keyword>Relapse</keyword>
  <keyword>intravenous Immunoglobulins</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Immunosuppressant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

